The Predictive Value of Carotid Ultrasonography With Cardiovascular Risk Factors—A “SPIDER” Promoting Atherosclerosis
crispr trials :: Article Creator Creating The World's First CRISPR Medicine, For Sickle Cell Disease When Vijay Sankaran was an MD-PhD student at Harvard Medical School in the mid-2000s, one of his first clinical encounters was with a 24-year-old patient whose sickle cell disease left them with almost weekly pain episodes. "The encounter made me wonder, couldn't we do more for these patients?" said Sankaran, who is now the HMS Jan Ellen Paradise, MD Professor of Pediatrics at Boston Children's Hospital. Get more HMS news As a budding hematologist, Sankaran knew all too well that people with sickle cell disease — marked by malformed, sickle-shaped red blood cells that can aggregate and block small vessels — experience excruciating pain crises, tissue and organ damage, and shortened life expectancy. He also understood that the only treatment available at the time was hydroxyurea, which reduces sickling but isn't effec...